Table 2 Clinical trials in lymphoid malignancies testing selinexor as single agent or in combination
From: XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
NCT | Phase | Lymphoid malignancy | Therapeutic strategy/combination | Estimated enrollment | Status |
|---|---|---|---|---|---|
NCT01607892 | I | Hematologic malignancies | Selinexor | 285 | Not recruiting |
NCT02138786 | II | Richter’s transformation lymphoma | Selinexor | 26 | Terminated |
NCT02186834 | I/II | MM | Selinexor, liposomal doxorubicin, dexamethasone | 47 | Recruiting |
NCT02199665 | I | MM | Selinexor, carfilzomib, dexamethasone | 48 | Recruiting |
NCT02227251 | II | R/R DLBCL | Selinexor | 200 | Recruiting |
NCT02303392 | I | CLL, lymphoma | Selinexor, ibrutinib | 92 | Recruiting |
NCT02314247 | II | TCL | Selinexor | 16 | Terminated |
NCT02336815 | II | MM | Selinexor, dexamethasone | 210 | Recruiting |
NCT02343042 | I/II | MM | Selinexor, dexamethasone, bortezomib, pomalidomide | 201 | Recruiting |
NCT02389543 | I/II | MM | Selinexor, lenalidomide, dexamethasone | 34 | Withdrawn |
NCT02471911 | I | R/R aggressive B cell lymphoma | Selinexor, rituximab, etoposide, carboplatin, ifosfamide, dexamethasone | 18 | Recruiting |
NCT02741388 | I | R/R B cell lymphoma | Selinexor, rituximab, dexamethasone, oxaliplatin, cisplatin, cytarabine, gemcitabine | 60 | Recruiting |